Table 1. Comparison of baseline and clinical characteristics, cytomegalovirus (CMV) serological test results, and polymerase chain reaction (PCR) results in 2 groups of patients with Guillain-Barré syndrome (GBS).
. In addition, serological studies may be biased toward certain types of CMV, as was suggested by Steininger et al. [1] . This would also have implications for further delineating patients with GBS into pathogenic subgroups, since some reports indicate that patients with positive CMV serological test results are younger; have a clinical variant characterized by severe involvement of motor, sensory, and cranial nerves and a prolonged progressive active phase; and have cross-reactive antibodies to the ganglioside GM2 [3, 4] . The presence of CMV in CSF may also suggest that endogenous reactivation of CMV infection within the central nervous system does occur and that these patients may profit from antiviral therapy [1] . The interesting findings of Steininger et al. [1] prompted us to investigate the presence of CMV DNA by PCR in our own collection of CSF samples from patients with GBS. We have collected acute-phase, pretreatment CSF samples from 170 (43%) of 397 patients with GBS participating in multicenter Dutch GBS trials [5, 6] . These patients did not differ clinically from the remaining patients. All patients fulfilled diagnostic criteria for GBS, were in the acute phase of disease (!2 weeks between first signs of weakness and randomization into the study group), and were unable to walk independently [6] . The patients we studied were comparable to those studied by Steininger et al. [1] with regard to age, frequency of positive CMV IgM serological test results [2] , (estimated) time interval to lumbar puncture, and CSF protein level (table 1) . Serological evidence of a recent CMV infection was detected in 22 (14%) of 159 patients (table 1 ). In contrast, we could detect CMV DNA in CSF from only a single patient with GBS. This patient also had serum CMV-specific IgM antibodies.
The discrepancy between our results and those of Steininger et al. [1] is remarkable, since a method with similar assay characteristics (as determined by quality-control proficiency testing) was used by the 2 reference laboratories. Random errors in our study are unlikely, considering the large number of patients included. Patient selection cannot be excluded, although both study groups were similar with respect to relevant clinical characteristics and frequency of positive CMV IgM serological test results. Steininger et al. [1] tested patients for CMV DNA in CSF and serum only when CMVspecific IgG or IgM antibodies were present, which resulted in selection of 42 of 65 identified patients with GBS. Our patients may have been more severely affected, as indicated by the larger proportion of patients who required ventilation in our group and by our inclusion criterion requiring that patients be unable to walk independently. Furthermore, the time interval between the onset of GBS and lumbar puncture was defined slightly differently in our study. However, the CSF protein content and the observed time intervals were not significantly different between the groups, indicating that the CSF was obtained at about the same time dur-ing the acute phase of the disease. Steininger et al. [1] reported that none of the 5 patients with positive CMV IgM serological test results had CMV DNA present in CSF. Of all of their serum samples that were positive for CMV DNA, only 2 (15%) had CMV-specific IgM antibodies. Furthermore, in only 3 (7%) of their patients could CMV DNA be detected in both CSF and serum. The lack of demonstrable CMV DNA in our patients raises the question of whether there are geographical differences in the incidence of CMV-related GBS. More data from other laboratories are required to clarify the role of intrathecal CMV in the pathogenesis of GBS and, especially, to suggest the potential beneficial use of antiviral therapy in this situation. 
